| Steven M Glanz, | |
|
7112 Beracasa Way, Suite 125, Boca Raton, FL 33433 | |
| (561) 322-8545 | |
| Not Available |
| Full Name | Steven M Glanz |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 7112 Beracasa Way, Boca Raton, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003925173 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | ME58607 (Florida) | Secondary |
| 207N00000X | Dermatology | ME58607 (Florida) | Primary |
| Entity Name | Adult And Pediatric Dermatology Practitioners P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487613907 PECOS PAC ID: 3971678947 Enrollment ID: O20080826000808 |
News Archive
"When President Obama made a landmark speech against modern slavery on Tuesday, many of us in the news media shrugged," but women survivors of human trafficking "noticed," Nicholas Kristof writes in his New York Times column.
A skin pigmentation mechanism that can darken the color of human skin as a natural defense against ultraviolet (UV)-associated cancers has been discovered by scientists at Massachusetts General Hospital (MGH).
The U.S. Food and Drug Administration today approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the market-leading PROMETHEUS® IBD Serology 7.
› Verified 7 days ago
| Entity Name | Onspot-fl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144827577 PECOS PAC ID: 3678984937 Enrollment ID: O20201118001475 |
News Archive
"When President Obama made a landmark speech against modern slavery on Tuesday, many of us in the news media shrugged," but women survivors of human trafficking "noticed," Nicholas Kristof writes in his New York Times column.
A skin pigmentation mechanism that can darken the color of human skin as a natural defense against ultraviolet (UV)-associated cancers has been discovered by scientists at Massachusetts General Hospital (MGH).
The U.S. Food and Drug Administration today approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the market-leading PROMETHEUS® IBD Serology 7.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven M Glanz, 1180 Sw 18th St, Boca Raton, FL 33486-6762 Ph: (561) 322-8545 | Steven M Glanz, 7112 Beracasa Way, Suite 125, Boca Raton, FL 33433 Ph: (561) 322-8545 |
News Archive
"When President Obama made a landmark speech against modern slavery on Tuesday, many of us in the news media shrugged," but women survivors of human trafficking "noticed," Nicholas Kristof writes in his New York Times column.
A skin pigmentation mechanism that can darken the color of human skin as a natural defense against ultraviolet (UV)-associated cancers has been discovered by scientists at Massachusetts General Hospital (MGH).
The U.S. Food and Drug Administration today approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the market-leading PROMETHEUS® IBD Serology 7.
› Verified 7 days ago
Stefanie S Gold, PA-C Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4601 N Federal Hwy, Boca Raton, FL 33431 Phone: 561-362-8000 Fax: 561-437-6806 | |
Michele J. Moraes, M.D., P.A. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9325 Glades Rd, Suite 107, Boca Raton, FL 33434 Phone: 561-883-7770 | |
Charles A Buchbinder, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2499 West Glades Road, Suite 310, Boca Raton, FL 33431 Phone: 561-395-7704 Fax: 561-395-8860 | |
Dr. Angela Giancola Weatherall, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7050 W Palmetto Park Rd, Suite 30, Boca Raton, FL 33433 Phone: 561-353-3376 Fax: 561-404-1170 | |
Larry Don Garland, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1905 Clint Moore Rd Ste 103, Boca Raton, FL 33496 Phone: 561-241-9667 Fax: 561-241-4474 | |
Robert Anthony Sarro, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St Ste 2d, Boca Raton, FL 33486 Phone: 561-862-5021 Fax: 561-862-5024 |